Valuation : StemCells Inc

Market Cap 99.4M 85.83M 80.45M 73.46M 138M 9.48B 139M 953M 372M 4.8B 373M 365M 15.92B P/E 2026 *
-4.72x
P/E 2027 * -4.31x
Enterprise Value 99.4M 85.83M 80.45M 73.46M 138M 9.48B 139M 953M 372M 4.8B 373M 365M 15.92B EV / Sales 2026 *
62.2x
EV / Sales 2027 * 11.3x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
08-14 B. Riley Adjusts Price Target on Microbot Medical to $4 From $5, Maintains Buy Rating MT
08-11 Microbot Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-11 Microbot Medical Inc. Announces Revenue Results for the Second Quarter Ended June 30, 2026 CI
06-23 Microbot Medical Announces First Health System in Pennsylvania to Adopt the Liberty Endovascular Robotic System CI
06-16 Microbot Medical Inc. Enters Into Agreement With Lovell Government Services To Expand Access For America?s Veteran And Military Patient Populations CI
06-16 Microbot Medical Enters Agreement Expanding Access to Federal Healthcare Systems MT
06-09 Microbot Medical Inc. Announces A Notable Health System as the First in Michigan to Adopt the Liberty Endovascular Robotic System CI
06-02 Microbot Medical Inc. Secures First North Carolina Healthcare System to Adopt the LIBERTY Endovascular Robotic System CI
05-26 Microbot Medical Inc. Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic System CI
05-18 Microbot Medical Inc. - Shareholder/Analyst Call
05-14 Microbot Medical recorded revenue during its quarter ended March 31, benefiting from limited market release of Liberty System RE
05-13 Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-05 Microbot Medical®'s Liberty® endovascular robotic system is now adopted by multiple accounts across key territories including two Access-PVI pivotal clinical trial sites RE
Manager TitleAgeSince
Chief Executive Officer 54 1988-08-01
Director of Finance/CFO 47 2022-03-31
Chief Operating Officer - 2025-01-20
Director TitleAgeSince
Chairman 54 2012-12-31
Director/Board Member 61 2016-11-27
Director/Board Member 65 2017-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-19.35%+575.21% - - 99.4M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -3.31%-1.06%+80.42%+111.08% 30.51B
Weighted average by Cap. -1.71%-1.06%+96.28%+129.03%

Financials

2026 *2027 *
Net sales 1.6M 1.38M 1.29M 1.18M 2.22M 152M 2.23M 15.33M 5.99M 77.12M 6M 5.87M 256M 8.8M 7.6M 7.12M 6.5M 12.24M 839M 12.29M 84.41M 32.97M 425M 33.04M 32.32M 1.41B
Net income -21.13M -18.25M -17.1M -15.62M -29.39M -2.02B -29.51M -203M -79.17M -1.02B -79.34M -77.61M -3.38B -23.92M -20.66M -19.36M -17.68M -33.27M -2.28B -33.41M -229M -89.63M -1.15B -89.81M -87.86M -3.83B
Net Debt - -
Logo StemCells Inc
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-